Johnson & Johnson (JNJ)

Johnson & Johnson presents new data showing high rates of complete skin clearance achieved at Week 24 and Week 52 in ICONIC-ADVANCE 1 and 2 studies

For investors looking to rebalance in Q2, here are three stocks that combine growth and defense to help investors stay invested during volatile markets

Johnson & Johnson is expected to announce its first-quarter results next month, and analysts are projecting a single-digit decline in its EPS.

These are two dividend stocks that you can confidently buy, hold, and forget about for decades.

In today’s highly volatile market, this simple 3-ETF portfolio combines both steady income and long-term upside.

Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill

RARITAN, N.J. , March 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing...

97% of patients reported no very bothersome visual disturbances, like halos or glare, with TECNIS PureSee IOL 1 97% of...

DGRO may stand out for investors looking for an ETF focused not only on the highest dividend yields, but on quality dividend payers likely to be stable.

Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression – free survival and overall survival versus standard of care regimens